Transplantation, AutologousMultiple MyelomaHematopoietic Stem Cell TransplantationStem Cell TransplantationMelphalanPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsTransplantation, HomologousTransplantation ConditioningCombined Modality TherapyTreatment OutcomeRemission InductionSalvage TherapyStem CellsDisease-Free SurvivalCyclophosphamideEtoposideHodgkin DiseaseBoronic AcidsMyeloablative AgonistsRecurrenceLymphoma, Non-HodgkinPyrazinesCytarabineCarmustineSurvival RateHematopoietic Stem Cell MobilizationBone Marrow TransplantationGraft vs Host DiseaseVincristineThalidomideThiotepaBone Marrow PurgingSurvival AnalysisHematologic NeoplasmsDexamethasoneAmyloidosisWhole-Body IrradiationDoxorubicinLymphoma, Mantle-CellRetrospective StudiesPrognosisHematopoietic Stem CellsBusulfanAntineoplastic Agents, AlkylatingAntineoplastic AgentsGraft SurvivalFollow-Up StudiesAntibodies, Monoclonal, Murine-DerivedAutograftsAntigens, CD34Lymphoma, FollicularLymphoma, T-Cell, PeripheralInduction ChemotherapyPrednisoneLiver TransplantationIfosfamideTime FactorsLeukemia, Plasma CellLymphomaLeukapheresisGranulocyte Colony-Stimulating FactorMaintenance ChemotherapyMesenchymal Stem Cell TransplantationPodophyllotoxinNeoplasm, ResidualMyeloma ProteinsTransplantation ChimeraLymphoma, Large B-Cell, DiffuseTissue DonorsLeukemia, Myeloid, AcuteCord Blood Stem Cell TransplantationCell TransplantationLymphoma, B-CellBone MarrowMyelodysplastic SyndromesKidney TransplantationNeoplasms, Second PrimaryEnteropathy-Associated T-Cell LymphomaEmbryonic Stem CellsMitoxantroneIdarubicinBlood Component RemovalImmunoglobulin Light ChainsInfusions, SpinalCisplatinProspective StudiesAntibodies, MonoclonalPlasma CellsImmunosuppressive AgentsCarboplatinAdult Stem CellsParaproteinemiasNeoplasm Recurrence, LocalDrug Administration ScheduleFatal OutcomeChemotherapy, AdjuvantHistocompatibility TestingFeasibility StudiesCell Differentiation